S
Susan L. Fink
Researcher at University of Washington
Publications - 52
Citations - 8472
Susan L. Fink is an academic researcher from University of Washington. The author has contributed to research in topics: Pyroptosis & Medicine. The author has an hindex of 19, co-authored 43 publications receiving 6548 citations. Previous affiliations of Susan L. Fink include Yale University.
Papers
More filters
Journal ArticleDOI
Pyroptosis: host cell death and inflammation
TL;DR: Pyroptosis, or caspase 1-dependent cell death, is inherently inflammatory, is triggered by various pathological stimuli, such as stroke, heart attack or cancer, and is crucial for controlling microbial infections.
Journal ArticleDOI
Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells
Susan L. Fink,Brad T. Cookson +1 more
TL;DR: A wide variety of pathogenic microorganisms have been demonstrated to cause eukaryotic cell death, either as a consequence of infecting host cells or by producing toxic products, and apoptosis in many of these systems is characterized as apoptosis.
Journal ArticleDOI
Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages.
Susan L. Fink,Brad T. Cookson +1 more
TL;DR: This mechanism of caspase‐1‐mediated cell death provides additional experimental evidence supporting pyroptosis as a novel pathway of inflammatory programmed cell death.
Journal ArticleDOI
Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series
Benjamin T. Bradley,Heather Maioli,Robert Johnston,Irfan Chaudhry,Susan L. Fink,Haodong Xu,Behzad Najafian,Gail H. Deutsch,J Matthew Lacy,Timothy L. Williams,Nicole A. Yarid,Desiree A. Marshall +11 more
TL;DR: In this paper, the authors provide a clinicopathological report of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases by documenting histopathological changes and evidence of SARS CoV2 tissue tropism.
Journal ArticleDOI
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.
Andrew Bryan,Gregory Pepper,Mark H. Wener,Susan L. Fink,Chihiro Morishima,Anu Chaudhary,Keith R. Jerome,Keith R. Jerome,Patrick C. Mathias,Alexander L. Greninger,Alexander L. Greninger +10 more
TL;DR: It is expected that the availability of high-quality serological testing will be a key tool in the fight against SARS-CoV-2 as the limited circulation of the virus in the western United States.